Regulation of gene expression by the proto-oncogene BCL-6

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 1, 2002, Pages 1-9

  Dent, Alexander L ^a   Vasanwala, Farha H ^a   Toney, Lisa M ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

BCL 6; BCL 6 target genes; Lymphoma; Transcriptional regulation

Indexed keywords

CD23 ANTIGEN; CD69 ANTIGEN; CHEMOKINE; CYCLIN D2; HERMES ANTIGEN; IMMUNOGLOBULIN E; REPRESSOR PROTEIN; STAT PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR;

B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING SITE; CELL CYCLE; CELL MIGRATION; CHROMOSOME TRANSLOCATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; GERMINAL CENTER; HUMAN; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; ONCOGENE BCL 6; PHENOTYPE; POINT MUTATION; PROMOTER REGION; PROTO ONCOGENE; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTION FACTORS;

EID: 0036142276     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00164-0     Document Type: Review

References (78)

1. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma
2. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6
3. Identification of genetic lesions associated with diffuse large-cell lymphoma
4. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma
5. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma
6. Rearrangement of the bcl-6 gene in Hodgkin's disease, lymphocyte predominant type
7. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas
8. BCL6 rearrangement in a patient with mantle cell lymphoma
9. Rearrangements of the BCL6 gene and chromosome aberrations affecting 3q27 in 54 patients with non-Hodgkin's lymphoma
10. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma
11. Somatic mutation of BCL-6 genes can occur in the absence of V(H) mutations in chronic lymphocytic leukemia
12. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia
13. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation
14. Internal deletions within the BCL6 gene in B-cell non-Hodgkin's lymphoma
15. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma
16. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis
17. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci
18. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes
19. BCL-6 protein is expressed in germinal-center B cells
20. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts
21. Molecular biology of Burkitt's lymphoma
22. Bcl-2: an antidote to programmed cell death
23. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
24. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18)
25. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large- cell lymphoma [see comments]
26. BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma
27. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas
28. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients
29. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma
30. BCL-6 expression during B-cell activation
31. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome
32. The POZ domain: a conserved protein-protein interaction motif
33. The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila
34. BCL-6 is phosphorylated at multiple sites in its serine- and proline- clustered region by mitogen-activated protein kinase (MAPK) in vivo
35. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor
36. Transcriptional repression by the proto-oncogene BCL-6
37. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor
38. BCL6 encodes a sequence-specific DNA-binding protein
39. Recognition DNA sequence of a novel putative transcription factor, BCL6
40. Germinal centers
41. The BCL6 gene is predominantly expressed in keratinocytes at their terminal differentiation stage
42. BCL6 can repress transcription from the human immunodeficiency virus type I promoter/enhancer region
43. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain
44. Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression
45. The BCL-6 POZ domain and other POZ domains interact with the co- repressors N-CoR and SMRT
46. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein
47. BCoR, a novel corepressor involved in BCL-6 repression
48. Co-repressors 2000
49. Histone deacetylases, transcriptional control, and cancer
50. Histone deacetylases: silencers for hire
51. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control
52. BCL-6 regulates chemokine gene transcription in macrophages, Nat
53. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci
54. STATs: signal transducers and activators of transcription
55. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
56. STATs, cytokine signal transduction, and immunoregulation: are we there yet?
57. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity
58. Control of inflammation, cytokine expression, and germinal center formation by BCL-6
59. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching
60. Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4
61. The BCL-6 proto-oncogene controls germinal-centre formation and Th2- type inflammation
62. Disruption of the Bcl6 gene results in an impaired germinal center formation
63. T helper type 2 inflammatory disease in the absence of IL-4 and STAT6
64. Functional diversity of helper T lymphocytes
65. The Th1/Th2 paradigm
66. The role of Bcl6 in mature cardiac myocytes
67. The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells
68. Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X(L)
69. DNA replication progresses on the periphery of nuclear aggregates formed by the BCL6 transcription factor
70. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor
71. Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product
72. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene
73. Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF
74. Chemokines
75. Chemokines and leukocyte traffic